MedTrace Logo

TKI Discontinuation in CML Patients of China

NCT03251352 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 98

Last updated 2022-03-16

No results posted yet for this study

Summary

The primary objective of this study is to describe the maintenance of the molecular remission after tyrosine kinase inhibitor (TKI) disconnection in chronic myeloid leukaemia (CML) patients in China in the real-world clinical practice setting. This is a post-marketing, non-interventional, single-arm, prospective registry study in adult patients with chronic phase (CP) and accelerated phase (AP) in China. Patients will be recruited consecutively from the study sites during the enrollment period. The enrolled patients will be undertaking TKI discontinuation under the conditions of informed consent and frequent monitoring according to the clinical guideline.

Conditions

  • Leukemia
  • Myelogenous
  • Chronic
  • BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia)
  • Positive

Sponsors & Collaborators

  • Shenzhen Second People's Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2022-09-30
Completion
2022-10-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03251352 on ClinicalTrials.gov